aglatimagene besadenovec
candel therapeutics
['sclc', 'can-2409', 'nsclc']
lead investigator, and candel present phase 2 #data on can-2409 showing cytotoxic t cell response &amp; disease control in patients with #nsclc at #asco22. view our poster here: 
Candel Therapeutics is an oncolytic viral immunotherapy company empowering the patient's immune system to fight disease.